High-density lipoprotein cholesterol to apolipoprotein A1 ratio and all-cause mortality among incident peritoneal dialysis patients

被引:4
作者
Zeng, Chuanfei [2 ]
Yan, Caixia [1 ]
Guo, Shan [3 ]
Zhu, Hengmei [1 ]
Chen, Yanbing [1 ]
Zhan, Xiaojiang [1 ]
机构
[1] Nanchang Univ, Affiliated Hosp 1, Dept Nephrol, 17 Yongwai St, Nanchang 330006, Jiangxi, Peoples R China
[2] Nanchang Univ, Jiangxi Med Coll, Nanchang 330006, Jiangxi, Peoples R China
[3] Jiangxi Univ Chinese Med, Nanchang 330006, Jiangxi, Peoples R China
关键词
All-cause mortality; Apolipoprotein A1; High-density lipoprotein cholesterol; Peritoneal dialysis; Cardiovascular disease; I RATIO; HDL-C; CARDIOVASCULAR RISK; BIOMARKER;
D O I
10.1016/j.numecd.2021.09.008
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aims: The ratio of high-density lipoprotein cholesterol to apolipoprotein A1 (HAR) is associated with all-cause mortality in nonchronic kidney disease patients, but its role in predicting all-cause mortality in patients undergoing peritoneal dialysis (PD) is still unclear. The purpose of this study was to investigate the relationship between HAR and all-cause mortality in patients with PD. Methods and results: The medical records of 1199 patients with PD from November 1, 2005, to August 31, 2019, were collected retrospectively. The main outcome was defined as all-cause mortality. The HAR was divided into three groups by X-tile software. The association between HAR and all-cause mortality was evaluated by Cox models. The Kaplan-Meier method was used for the survival curve. The median follow-up period was 35 months (interquartile range: 20-57 months), with a total of 326 deaths recorded. After multiple adjustments, the risk of all-cause mortality in the high HAR group was 1.96-fold higher than that in the low HAR group (hazard ratio: 1.96; 95% CI, 1.22 to 3.15; P Z 0.005). The restricted cubic splines showed that the risk of all-cause mortality increased gradually when HAR was >0.37. In the stratified analysis, a high HAR was linked to a high risk of all-cause mortality in males, patients under 55 years old, and patients without diabetes or cardiovascular disease (CVD). Conclusion: This study suggests that HAR is independently related to all-cause mortality in PD patients, especially in males, patients under 55 years old, and patients without diabetes or CVD. (c) 2021 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:3457 / 3463
页数:7
相关论文
共 33 条
[1]   Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients A Meta-Analysis [J].
Boekholdt, S. Matthijs ;
Arsenault, Benoit J. ;
Hovingh, G. Kees ;
Mora, Samia ;
Pedersen, Terje R. ;
LaRosa, John C. ;
Welch, K. M. A. ;
Amarenco, Pierre ;
DeMicco, David A. ;
Tonkin, Andrew M. ;
Sullivan, David R. ;
Kirby, Adrienne ;
Colhoun, Helen M. ;
Hitman, Graham A. ;
Betteridge, D. John ;
Durrington, Paul N. ;
Clearfield, Michael B. ;
Downs, John R. ;
Gotto, Antonio M., Jr. ;
Ridker, Paul M. ;
Kastelein, John J. P. .
CIRCULATION, 2013, 128 (14) :1504-1512
[2]   High Density Lipoprotein Cholesterol and the Risk of All-Cause Mortality among US Veterans [J].
Bowe, Benjamin ;
Xie, Yan ;
Xian, Hong ;
Balasubramanian, Sumitra ;
Zayed, Mohamed A. ;
Al-Aly, Ziyad .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2016, 11 (10) :1784-1793
[3]   X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization [J].
Camp, RL ;
Dolled-Filhart, M ;
Rimm, DL .
CLINICAL CANCER RESEARCH, 2004, 10 (21) :7252-7259
[4]   DIVERGENT LEVELS OF HIGH-DENSITY-LIPOPROTEIN CHOLESTEROL AND APOLIPOPROTEIN A-I IN CHILDREN - THE BOGALUSA HEART-STUDY [J].
FREEDMAN, DS ;
SRINIVASAN, SR ;
WEBBER, LS ;
BERENSON, GS .
ARTERIOSCLEROSIS, 1987, 7 (04) :347-353
[5]   High-density lipoprotein cholesterol efflux capacity and cardiovascular risk in autoimmune and non-autoimmune diseases [J].
Hafiane, Anouar ;
Favari, Elda ;
Daskalopoulou, Stella S. ;
Vuilleumier, Nicolas ;
Frias, Miguel A. .
METABOLISM-CLINICAL AND EXPERIMENTAL, 2020, 104
[6]   High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk [J].
Hafiane, Anouar ;
Genest, Jacques .
BBA CLINICAL, 2015, 3 :175-188
[7]   Unravelling HDL-Looking beyond the Cholesterol Surface to the Quality Within [J].
Kajani, Sarina ;
Curley, Sean ;
McGillicuddy, Fiona C. .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (07)
[8]   Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients [J].
Keene, Daniel ;
Price, Clare ;
Shun-Shin, Matthew J. ;
Francis, Darrel P. .
BMJ-BRITISH MEDICAL JOURNAL, 2014, 349
[9]   High-Density Lipoprotein Cholesterol and Cause-Specific Mortality in Individuals Without Previous Cardiovascular Conditions The CANHEART Study [J].
Ko, Dennis T. ;
Alter, David A. ;
Guo, Helen ;
Koh, Maria ;
Lau, Geoffrey ;
Austin, Peter C. ;
Booth, Gillian L. ;
Hogg, William ;
Jackevicius, Cynthia A. ;
Lee, Douglas S. ;
Wijeysundera, Harindra C. ;
Wilkins, John T. ;
Tu, Jack V. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (19) :2073-2083
[10]   Importance of high-density lipoprotein quality: evidence from chronic kidney disease [J].
Kon, Valentina ;
Ikizler, T. Alp ;
Fazio, Sergio .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2013, 22 (03) :259-265